Toll-like Receptors Regulate MIF Expression in Benign Lymphoepithelial Lesion of the Lacrimal Gland

Mawulikplimi Yao Adzavon; Pengxiang Zhao; Xujuan Zhang; Xin Zhang; Limin Wang; Tarekegn Gebreyesus Abisso; Xuemei Ma

doi:10.21467/ias.4.1.27-34

Authors

Mawulikplimi Yao Adzavon College of Life Science and Bio-engineering, Beijing University of Technology
Pengxiang Zhao College of Life Science and Bio-engineering, Beijing University of Technology
Xujuan Zhang College of Life Science and Bio-engineering, Beijing University of Technology
Xin Zhang Beijing University of Technology
Limin Wang College of Life Science and Bio-engineering, Beijing University of Technology
Tarekegn Gebreyesus Abisso College of Life Science and Bio-engineering, Beijing University of Technology
Xuemei Ma College of Life Science and Bio-engineering, Beijing University of Technology

DOI:

https://doi.org/10.21467/ias.4.1.27-34

Abstract

Despite a perpetual increase in the prevalence of benign lymphoepithelial lesion, data on the mechanisms governing its pathogenesis are still missing. Thus, we aimed in the present study to evaluate whether TLRs could regulate the expression of the pleiotropic pro-inflammatory and tumor-related cytokine MIF in BLEL. Using gene expression profiling and protein expression analysis methods, we found that TLRs were overexpressed and that their signaling pathways were activated in BLEL. We have also confirmed in tissues biopsies, the overexpression of MIF reported previously in plasma of BLEL specimen. The analysis of the TLR7/8 impact on the expression of MIF in BLEL primary cells showed that when activated, TLR7/8 stimulate mainly BLEL lymphocytes to release MIF but not the fibroblast-like cells. No significant change was observed when MIF expression was investigated at the transcriptional level 24h post TLR7/8 activation. Taken together, these data suggest that TLR7 and TLR8 are activated in BLEL and may induce a cell type-dependent regulation of MIF secretion and expression.

Keywords:

Benign lymphoepithelial lesion, Lacrimal gland, Macrophage migration inhibitory factor, Pathogenesis, Toll-like receptors, Tumor

Downloads

Download data is not yet available.

References

M. Moriyama, A. Tanaka, T. Maehara, Y. Ohyama, M. Shimizu, H. Nakashima, J. N. Hayashida, S. Shinozaki, Y. Kubo, S. Furukawa, T. Kikuta, and S. Nakamura, “Clinical characteristics of Mikulicz's disease as an IgG4-related disease,” Clin Oral Investig, vol. 17, no. 9, pp. 1995-2002, Dec, 2013.

M. Yamamoto, H. Takahashi, M. Ohara, C. Suzuki, Y. Naishiro, H. Yamamoto, Y. Shinomura, and K. Imai, “A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease,” Mod Rheumatol, vol. 16, no. 6, pp. 335-40, 2006.

M. Yamamoto, H. Takahashi, S. Sugai, and K. Imai, “Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy),” Autoimmunity Reviews, vol. 4, no. 4, pp. 195-200, 4//, 2005.

Q. J. Li, P. X. Zhao, X. J. Zhang, Y. Yi, D. Y. Cheng, J. M. Ma, and X. M. Ma, “Association of the macrophage migration inhibitory factor promoter polymorphisms with benign lymphoepithelial lesion of lacrimal gland,” Int J Ophthalmol, vol. 10, no. 8, pp. 1229-1232, 2017.

T. Lang, A. Foote, J. P. Lee, E. F. Morand, and J. Harris, “MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus,” Front Immunol, vol. 6, pp. 577, 2015.

C. C. Nobre, J. M. de Araujo, T. A. Fernandes, R. N. Cobucci, D. C. Lanza, V. S. Andrade, and J. V. Fernandes, “Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer,” Pathol Oncol Res, Oct 23, 2016.

R. Fukaya, S. Ohta, T. Yaguchi, Y. Matsuzaki, E. Sugihara, H. Okano, H. Saya, Y. Kawakami, T. Kawase, K. Yoshida, and M. Toda, “MIF Maintains the Tumorigenic Capacity of Brain Tumor-Initiating Cells by Directly Inhibiting p53,” Cancer Res, vol. 76, no. 9, pp. 2813-23, May 1, 2016.

J. A. Baugh, and R. Bucala, “Macrophage migration inhibitory factor,” Crit Care Med, vol. 30, no. 1 Supp, pp. S27-s35, Jan, 2002.

H. Lue, R. Kleemann, T. Calandra, T. Roger, and J. Bernhagen, “Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease,” Microbes Infect, vol. 4, no. 4, pp. 449-60, Apr, 2002.

C. Popa, A. W. van Lieshout, M. F. Roelofs, A. Geurts-Moespot, P. L. van Riel, T. Calandra, F. C. Sweep, and T. R. Radstake, “MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis,” Cytokine, vol. 36, no. 1-2, pp. 51-6, Oct, 2006.

S. Akira, and K. Takeda, “Toll-like receptor signalling,” Nat Rev Immunol, vol. 4, no. 7, pp. 499-511, Jul, 2004.

N. J. Gay, M. F. Symmons, M. Gangloff, and C. E. Bryant, “Assembly and localization of Toll-like receptor signalling complexes,” Nat Rev Immunol, vol. 14, no. 8, pp. 546-58, Aug, 2014.

O. Takeuchi, and S. Akira, “Pattern Recognition Receptors and Inflammation,” Cell, vol. 140, no. 6, pp. 805-820, 3/19/, 2010.

Y. M. Adzavon, P. Zhao, B. Lv, M. Liu, X. Zhang, F. Xie, L. Yang, L. Shang, M. Zhang, Q. Li, and X. Ma, “TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs,” Cytokine, vol. 97, pp. 156-166, Sep, 2017.

S. Wada, S. Fujimoto, Y. Mizue, and J. Nishihira, “Macrophage migration inhibitory factor in the human ovary: presence in the follicular fluids and production by granulosa cells,” Biochem Mol Biol Int, vol. 41, no. 4, pp. 805-14, Apr, 1997.

J. D. Burton, S. Ely, P. K. Reddy, R. Stein, D. V. Gold, T. M. Cardillo, and D. M. Goldenberg, “CD74 is expressed by multiple myeloma and is a promising target for therapy,” Clin Cancer Res, vol. 10, no. 19, pp. 6606-11, Oct 01, 2004.

J. P. Salim, N. P. Goette, P. R. Lev, C. D. Chazarreta, P. G. Heller, C. Alvarez, F. C. Molinas, and R. F. Marta, “Dysregulation of stromal derived factor 1/CXCR4 axis in the megakaryocytic lineage in essential thrombocythemia,” Br J Haematol, vol. 144, no. 1, pp. 69-77, Jan, 2009.

Z. Liu, L. Yang, J. Xu, X. Zhang, and B. Wang, “Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma,” J Surg Res, vol. 166, no. 2, pp. 241-6, Apr, 2011.

J. Su, X. Chen, Y. Huang, W. Li, J. Li, K. Cao, G. Cao, L. Zhang, F. Li, A. I. Roberts, H. Kang, P. Yu, G. Ren, W. Ji, Y. Wang, and Y. Shi, “Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species,” Cell Death Differ, vol. 21, no. 3, pp. 388-396, 03//print, 2014.

R. M. Valente, E. Ehlers, D. Xu, H. Ahmad, A. Steadman, L. Blasnitz, Y. Zhou, L. Kastanek, B. Meng, and L. Zhang, “Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1,” PLoS One, vol. 7, no. 8, pp. e43317, 2012.

Y. Zhang, H. Yang, P. A. Barnie, P. Yang, Z. Su, J. Chen, Z. Jiao, L. Lu, S. Wang, and H. Xu, “The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer,” Int J Med Sci, vol. 11, no. 6, pp. 608-13, 2014.

K. C. Lai, S. C. Hsu, J. S. Yang, C. C. Yu, J. C. Lein, and J. G. Chung, “Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth,” J Cell Mol Med, vol. 19, no. 2, pp. 474-84, Feb, 2015.

A. Tanaka, M. Moriyama, H. Nakashima, K. Miyake, J. N. Hayashida, T. Maehara, S. Shinozaki, Y. Kubo, and S. Nakamura, “Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease,” Arthritis Rheum, vol. 64, no. 1, pp. 254-63, Jan, 2012.

T. Maehara, M. Moriyama, H. Nakashima, K. Miyake, J. N. Hayashida, A. Tanaka, S. Shinozaki, Y. Kubo, and S. Nakamura, “Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease,” Ann Rheum Dis, vol. 71, no. 12, pp. 2011-19, Dec, 2012.

E. Kudo-Tanaka, S. Nakatsuka, T. Hirano, M. Kawai, Y. Katada, M. Matsushita, S. Ohshima, M. Ishii, K. Miyatake, T. Tanaka, and Y. Saeki, “A case of Mikulicz's disease with Th2-biased cytokine profile: possible feature discriminable from Sjogren's syndrome,” Mod Rheumatol, vol. 19, no. 6, pp. 691-5, 2009.

G. Zhang, and S. Ghosh, “Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity,” J Clin Invest, vol. 107, no. 1, pp. 13-9, Jan, 2001.

G. Bonizzi, and M. Karin, “The two NF-κB activation pathways and their role in innate and adaptive immunity,” Trends in Immunology, vol. 25, no. 6, pp. 280-288.

T. Kawasaki, and T. Kawai, “Toll-like receptor signaling pathways,” Frontiers in immunology, vol. 5, 2014.

T. Roger, L. J. Schlapbach, A. Schneider, M. Weier, S. Wellmann, P. Marquis, D. Vermijlen, F. C. G. J. Sweep, L. Leng, R. Bucala, T. Calandra, and E. Giannoni, “Plasma Levels of Macrophage Migration Inhibitory Factor and d-Dopachrome Tautomerase Show a Highly Specific Profile in Early Life,” Frontiers in Immunology, vol. 8:26, 2017.

A. Zernecke, J. Bernhagen, and C. Weber, “Macrophage migration inhibitory factor in cardiovascular disease,” Circulation, vol. 117, no. 12, pp. 1594-602, Mar 25, 2008.

J. Bernhagen, R. Krohn, H. Lue, J. L. Gregory, A. Zernecke, R. R. Koenen, M. Dewor, I. Georgiev, A. Schober, L. Leng, T. Kooistra, G. Fingerle-Rowson, P. Ghezzi, R. Kleemann, S. R. McColl, R. Bucala, M. J. Hickey, and C. Weber, “MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment,” Nat Med, vol. 13, no. 5, pp. 587-96, May, 2007.

S. Alampour-Rajabi, O. El Bounkari, A. Rot, G. Muller-Newen, F. Bachelerie, M. Gawaz, C. Weber, A. Schober, and J. Bernhagen, “MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis,” Faseb j, vol. 29, no. 11, pp. 4497-511, Nov, 2015.

C. Klasen, K. Ohl, M. Sternkopf, I. Shachar, C. Schmitz, N. Heussen, E. Hobeika, E. Levit-Zerdoun, K. Tenbrock, M. Reth, J. Bernhagen, and O. El Bounkari, “MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling,” J Immunol, vol. 192, no. 11, pp. 5273-84, Jun 1, 2014.